Bimekizumab in Psoriasis: 3-Year Outcomes

• by Kathryn Wighton

• March 12, 2026

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

• by Nada Elbuluk, April W. Armstrong, Ronald Vender, Tina Bhutani, Lawrence Green, Laura K. Ferris, Vivian Laquer, Angela Moore, Jamie Weisman, Wenwen Zhang, Warren Winkelman, Melinda J. Gooderham

• May 16, 2026

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

• by Andrea Surnit

• April 20, 2026

• 2 min

Assessment of Tildrakizumab's Effectiveness and Safety in Patients with Moderate-to-Severe Plaque Psoriasis and Diabetes: Combined Analysis from reSURFACE 1 and reSURFACE 2 Trials

• by Jerry Bagel, Ranga Gogineni, Asif Shaikh, Mark G. Lebwohl

• March 16, 2026